Brief: FDA Approves Freenome’S Simplescreen™ Crc Blood-Based Screening Test Abbott To Commercialize In The U.S.
27/07/2026 13:09
BRIEF-FDA Approves Freenome’S Simplescreen™ Crc Blood-Based Screening Test Abbott To Commercialize In The U.S. July 27 (Reuters) - Perceptive Capital Solutions Corp FRNM.O:
FDA APPROVES FREENOME’S SIMPLESCREEN™ CRC BLOOD-BASED SCREENING TEST; ABBOTT TO COMMERCIALIZE IN THE U.S.
FREENOME- FREENOME TO RECEIVE $100 MILLION MILESTONE PAYMENT FROM ABBOTT FOR FDA APPROVAL
Source text: ID:nGNXr18mG
Further company coverage: FRNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Freenome
See all newsBrief: Freenome Expands Personalized Cancer Detection Portfolio With Simplescreen Lung Test
FDA approves Freenome's blood test for colorectal cancer screening (updated)
FDA approves Freenome's blood test for colorectal cancer screening
Brief: FDA Approves Freenome’S Simplescreen™ Crc Blood-Based Screening Test Abbott To Commercialize In The U.S.
Brief: Freenome And Perceptive Capital Solutions Corp Announce Business Combination Agreement